Search for 'Provider:Clinical and au:Castellano, Daniel'

Association of single nucleotide polymorphisms in IL8 and IL13 with sunitinib-induced toxicity in patients with metastatic renal cell carcinoma.

By Castellano, Daniel. European journal of clinical pharmacology, 2015 . 71(12):1477-84. , Formato Vancouver: Diekstra MH, Liu X, Swen JJ, Boven E, Castellano D, Gelderblom H et al. Association of single nucleotide polymorphisms in IL8 and IL13 with sunitinib-induced toxicity in patients with metastatic renal cell carcinoma. Eur J Clin Pharmacol. 2015 Dec;71(12):1477-84.

Place Hold on Association of single nucleotide polymorphisms in IL8 and IL13 with sunitinib-induced toxicity in patients with metastatic renal cell carcinoma.

Analysis of the Polycomb-related lncRNAs HOTAIR and ANRIL in bladder cancer.

By Martínez Fernández, Mónica | Dueñas, Marta | Segovia, Cristina | Rubio, Carolina | Fernández, María | Villacampa Aubá, Felipe | Duarte Ojeda, José Manuel | López Calderón, Fernando F | Gómez Rodríguez, María José | Castellano, Daniel | Rosa Kehrman, Federico de la | Rodríguez Peralto, José Luis | Paramio, Jesús M.. Clinical epigenetics, 2015 . 7:109. , Formato Vancouver: Martínez Fernández M, Feber A, Dueñas M, Segovia C, Rubio C, Fernandez M et al. Analysis of the Polycomb-related lncRNAs HOTAIR and ANRIL in bladder cancer. Clin Epigenetics. 2015 Oct 8;7:109.

Place Hold on Analysis of the Polycomb-related lncRNAs HOTAIR and ANRIL in bladder cancer.

Randomized, placebo-controlled, phase III trial of sunitinib plus prednisone versus prednisone alone in progressive, metastatic, castration-resistant prostate cancer.

By Castellano, Daniel. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014 . 32(2):76-82. , Formato Vancouver: Michaelson MD, Oudard S, Ou YC, Sengeløv L, Saad F, Houede N et al. Randomized, placebo-controlled, phase III trial of sunitinib plus prednisone versus prednisone alone in progressive, metastatic, castration-resistant prostate cancer. J Clin Oncol. 2014 Jan 10;32(2):76-82.

Place Hold on Randomized, placebo-controlled, phase III trial of sunitinib plus prednisone versus prednisone alone in progressive, metastatic, castration-resistant prostate cancer.

Phase I Study of Dovitinib (TKI258), an Oral FGFR, VEGFR, and PDGFR Inhibitor, in Advanced or Metastatic Renal Cell Carcinoma.

By Castellano, Daniel | López Martín, José Antonio. Clinical Cancer Research, 2013 . 19(5):1257-68. , Formato Vancouver: Angevin E, López-Martin JA, Lin CC, Gschwend JE, Harzstark A, Castellano D et al. Phase I study of dovitinib (TKI258), an oral FGFR, VEGFR, and PDGFR inhibitor, in advanced or metastatic renal cell carcinoma. Clin Cancer Res. 2013 Mar;19(5):1257-68.

Place Hold on Phase I Study of Dovitinib (TKI258), an Oral FGFR, VEGFR, and PDGFR Inhibitor, in Advanced or Metastatic Renal Cell Carcinoma.

Biological markers of cisplatin resistance in advanced testicular germ cell tumours

By Ballestín Carcavilla, Claudio | Castellano, Daniel | Cortés-Funes Castro, Hernán. Clinical and Translational Oncology, 2012 . 14(6):452-457. , Formato Vancouver: García-Velasco A, Durán I, García E, Tarón M, Ballestín C, Castellanos D, et al. Biological markers of cisplatin resistance in advanced testicular germ cell tumours. Clin Transl Oncol. 2012;14(6):452-7.

Place Hold on Biological markers of cisplatin resistance in advanced testicular germ cell tumours

Cost-effectiveness evaluation of sunitinib as first-line targeted therapy for metastatic renal cell carcinoma in Spain

By Castellano, Daniel. Clinical and Translational Oncology, 2011 . 13(12):869-877. , Formato Vancouver: Calvo Aller E, Maroto P, Kreif N, González Larriba JL, López-Brea M, Castellano D, et al. Cost-effectiveness evaluation of sunitinib as first-line targeted therapy for metastatic renal cell carcinoma in Spain. Clin Transl Oncol. 2011;13(12):869-77.

Place Hold on Cost-effectiveness evaluation of sunitinib as first-line targeted therapy for metastatic renal cell carcinoma in Spain